If you or someone you love is taking a GLP‑1 drug like Ozempic, Wegovy, or Mounjaro, you’ve probably heard a lot about rapid weight loss and improved blood sugar. Recently, though, new research has raised a different question: could these medications also increase the risk of bone and tendon injuries—and even conditions like osteoporosis and gout?


The answer isn’t simple. GLP‑1 drugs remain powerful, often life-changing tools for type 2 diabetes and obesity. But like any treatment, they come with trade‑offs. Understanding those trade‑offs helps you use them more safely, instead of being surprised months or years down the line.


In this guide, we’ll unpack what the latest evidence suggests about bone density, fractures, tendon problems, and related issues—then walk through practical, science-backed steps you can take to protect your body while on GLP‑1 therapy.


A pharmacist holding a box of GLP-1 medication such as Ozempic in a clinical setting
GLP‑1 medications like Ozempic have transformed diabetes and weight‑loss care, but new data highlight potential risks for bones and tendons.

As prescriptions for GLP‑1 agonists surge worldwide, researchers are now able to detect patterns of side effects that were harder to see in earlier, smaller trials. Some of those patterns are now pointing toward musculoskeletal health.


What Are GLP‑1 Drugs—And Why Are So Many People Taking Them?

GLP‑1 receptor agonists are medications that mimic a natural hormone called glucagon‑like peptide‑1. They help:

  • Increase insulin release after meals
  • Reduce appetite and slow stomach emptying (so you feel full longer)
  • Lower blood sugar and, in many people, body weight

Ozempic (semaglutide), Wegovy (a higher‑dose semaglutide for weight loss), Mounjaro (tirzepatide) and similar drugs have been rigorously studied for diabetes and obesity. They’ve shown impressive benefits for:

  • Improving blood sugar control
  • Supporting substantial weight loss
  • Reducing the risk of some cardiovascular events in people with diabetes and heart disease


What the New Research Says About Bone and Tendon Risks

Newer observational studies and large database analyses, including work reported by major outlets such as The Washington Post, suggest that people using GLP‑1 drugs may have a higher rate of:

  • Bone fractures and bone injuries
  • Tendon injuries (like Achilles or rotator cuff problems)
  • Conditions linked to bone and joint metabolism, including possible increases in osteoporosis and gout diagnoses

“Rapid, medically induced weight loss can alter bone turnover and muscle‑tendon loading, potentially affecting fracture risk and soft‑tissue injury patterns.”

— Summary of findings across multiple metabolic and bone health studies

It’s important to emphasize: these studies show associations, not proof that GLP‑1 drugs directly cause these problems. People on GLP‑1s often:

  • Lose weight rapidly
  • Change activity levels
  • May already have diabetes, obesity, or other conditions that influence bone and joint health

Those factors alone can affect bone density and tendon stress. But the pattern is strong enough that researchers are taking it seriously and calling for more focused clinical trials on musculoskeletal outcomes.


How GLP‑1 Therapy and Rapid Weight Loss Can Affect Your Bones

Weight loss is generally good for metabolic and cardiovascular health, but it doesn’t come free from a bone perspective—especially when it’s fast.

  1. Loss of bone density with weight loss

    Studies of various weight‑loss methods (surgery, diet, medications) show that when people lose substantial weight quickly, they often lose some bone mineral density, particularly at the hip and spine. Less body weight means:

    • Less mechanical loading on bones
    • Shifts in hormones that regulate bone turnover
  2. Potential changes in bone‑forming and bone‑breaking cells

    Some early laboratory and clinical data suggest GLP‑1 agonists may influence osteoblasts (bone‑forming cells) and osteoclasts (bone‑resorbing cells). The direction of this effect is not fully settled and may differ by drug, dose, and patient population.

  3. Nutrient intake may drop

    Because GLP‑1 drugs reduce appetite, people sometimes eat less overall and unintentionally cut calcium, vitamin D, and protein—three pillars of bone health.



Why Tendons May Be at Higher Risk on GLP‑1 Drugs

Tendons are the tough connective tissues that anchor muscle to bone. They adapt slowly to changes in load. When your body weight, posture, and activity level shift quickly—as often happens with GLP‑1‑driven weight loss—tendons can be caught in the middle.

Researchers propose a few plausible mechanisms:

  • Rapid biomechanical shifts – As you lose weight, the way you walk, run, or climb stairs changes. This can abruptly alter stress patterns on your Achilles, knees, hips, and shoulders.
  • Muscle loss alongside fat loss – Without resistance training and adequate protein, you may lose muscle mass. Weaker muscles can overload tendons.
  • Return to high‑impact exercise too quickly – Many people feel energized as the weight comes off and jump into running or intense classes faster than their tendons can adapt.

In our clinic, we’ve seen an uptick in Achilles and patellar tendon complaints in patients after rapid, medication‑assisted weight loss—especially among those who ramped up jogging or high‑impact workouts within a few months of starting GLP‑1 therapy.

— Sports medicine physician anecdotal observation

Osteoporosis and Gout: Should You Be Worried?

Some large database studies suggest increased diagnoses of osteoporosis and gout among GLP‑1 users compared with certain other treatments. Interpreting this requires nuance:

  • Osteoporosis

    The combination of pre‑existing risk factors (age, menopause, diabetes, prior inactivity), rapid weight loss, and possible direct drug effects may all contribute. For some patients, GLP‑1 therapy might simply bring existing risk to light when doctors start checking bone density more carefully.

  • Gout

    Gout flares are influenced by changes in weight, kidney function, hydration, and diet (especially rapid shifts in purine intake and alcohol). Some studies have flagged higher gout diagnoses in GLP‑1 users, but causation isn’t established. It may relate more to the dynamics of weight change than to the drug itself.



A Real‑World Story: Rapid Weight Loss, Surprising Tendon Pain

Consider “Maria,” a 52‑year‑old woman with long‑standing type 2 diabetes and obesity (this is a composite case based on several patients, not one individual).

  • She started semaglutide under the care of her endocrinologist.
  • Over 8 months, she lost 55 pounds, improved her A1C, and came off another diabetes medication.
  • Encouraged by her progress, she joined a high‑intensity interval training class three times a week.
  • Within 6 weeks, she developed sharp Achilles pain and trouble going down stairs.

A sports medicine evaluation found Achilles tendinopathy. Maria had lost weight quickly, gained confidence, and jumped into plyometrics and sprints that her tendons weren’t ready for. She was able to stay on her GLP‑1 medication, but:

  1. Switched to a progressive, lower‑impact strength and walking program
  2. Added calf‑strengthening and mobility work
  3. Worked with a dietitian to ensure adequate protein, calcium, and vitamin D

Over several months, her tendon pain improved, and she continued to maintain her weight loss. Her story illustrates a key theme: the medication can stay, but the strategy around movement and nutrition may need to change.


Before vs. After: Musculoskeletal Health on GLP‑1 Therapy

Side by side comparison of a person doing light walking versus structured strength training to protect joints
A thoughtful transition from low activity to structured strength and low‑impact exercise can reduce bone and tendon stress during rapid weight loss.

Here’s a quick comparison of a higher‑risk versus a more protective approach while using GLP‑1 medications:

Higher‑Risk Pattern More Protective Pattern
Rapid weight loss with no resistance training Progressive, twice‑weekly strength training from early in treatment
Very low calorie intake, little focus on protein or calcium Adequate protein (often 1.0–1.2 g/kg/day unless restricted), plus calcium and vitamin D
Jumping straight into running or high‑impact classes Starting with walking, cycling, swimming, then gradually adding impact if tolerated
Ignoring new joint or tendon pain Early evaluation of persistent pain & adjustment of training plan

8 Practical Ways to Protect Your Bones and Tendons on GLP‑1 Drugs

You don’t have to choose between metabolic health and musculoskeletal health. With a few deliberate steps—and close collaboration with your healthcare team—you can support both.

  1. Ask about your baseline bone health

    If you’re over 50, postmenopausal, have a history of fractures, long‑term steroid use, or other osteoporosis risk factors, ask whether a DEXA scan (bone density test) is appropriate before or soon after starting GLP‑1 therapy.

  2. Prioritize strength training early

    Aim for at least 2 non‑consecutive days per week of resistance training that targets major muscle groups. Body‑weight exercises, resistance bands, or light dumbbells are a good starting point.

  3. Protect your protein intake

    Work with a dietitian if possible. Many adults benefit from about 1.0–1.2 grams of protein per kilogram of body weight per day (unless you have kidney or liver disease that requires restriction). Spread protein across meals to support muscle and tendon health.

  4. Ensure adequate calcium and vitamin D

    Typical targets are around 1,000–1,200 mg/day of calcium and 600–800 IU/day of vitamin D for most adults, though some may need more or less. Get as much as you can from food first; supplements can fill in the gaps as advised by your clinician.

  5. Increase activity gradually

    Follow the “10% rule”: don’t increase your total weekly exercise volume by more than about 10% per week. Tendons adapt slowly—give them time.

  6. Listen to early warning signs

    Persistent pain in the heel, knee, hip, shoulder, or elbow—especially if it worsens with use—warrants attention. Rest, modify your activity, and seek assessment if it doesn’t improve over 1–2 weeks.

  7. Discuss medication adjustments, not abrupt stopping

    If you develop significant bone or tendon problems, talk with your prescriber about dose changes or alternative therapies. Stopping GLP‑1 drugs suddenly can sometimes lead to rapid weight regain, which brings its own risks.

  8. Coordinate care among specialists

    For complex cases (prior osteoporosis, recurrent gout, significant tendon issues), your primary clinician may involve an endocrinologist, rheumatologist, or sports medicine specialist to tailor your plan.


Quick Visual: Balancing GLP‑1 Benefits and Bone/Tendon Risks

Doctor and patient reviewing health information on a tablet together
Partnering closely with your healthcare team helps you balance the benefits of GLP‑1 medications with proactive protection of your bones and tendons.

Think of your GLP‑1 journey as a three‑part checklist:

  • Monitor: Bone density when indicated, labs (including vitamin D), and any new musculoskeletal symptoms.
  • Move: Combine strength training with low‑impact cardio, advancing intensity slowly.
  • Maintain: Adequate nutrients, realistic weight‑loss pace, and regular follow‑ups with your care team.

What We Still Don’t Know (Yet)

Even with growing data, there are important unanswered questions:

  • Are some GLP‑1 or dual agonist drugs riskier for bones or tendons than others?
  • How much of the risk comes from the drug itself versus the speed and amount of weight lost?
  • Which patients are most vulnerable—and which protective strategies work best?

Large, long‑term randomized trials specifically designed to track bone density, fracture rates, and tendon injuries are still limited. Until we have those, clinicians rely on:

  • Existing randomized trial data (which often weren’t focused on musculoskeletal outcomes)
  • Real‑world observational studies and insurance‑claims analyses
  • Clinical experience and related research on weight loss, bone metabolism, and exercise science

That’s why it’s wise to stay informed and to treat new findings as signals to guide monitoring and lifestyle—not as a reason to panic or abruptly abandon a therapy that may be helping your metabolic health.


How to Talk With Your Doctor—and Where to Find Reliable Information

When you bring up bone or tendon concerns with your clinician, consider asking:

  • “Given my age and history, should we screen for osteoporosis now or later?”
  • “What kind of exercise plan do you recommend while I’m on this medication?”
  • “Can you refer me to a dietitian or physical therapist who understands GLP‑1 therapy?”
  • “What specific symptoms should prompt me to call you right away?”

For up‑to‑date, evidence‑based information on GLP‑1 drugs and bone health, look for resources from:


Person writing questions for a doctor visit in a notebook
Preparing questions before your appointment helps you make the most of limited clinic time and advocate for your bone and tendon health.

Bringing It All Together: Informed, Not Afraid

GLP‑1 medications like Ozempic have opened the door to better blood sugar control and meaningful weight loss for millions of people. Emerging data about bone and tendon risks don’t erase those benefits—but they do remind us that there is no “magic shot” without trade‑offs.


By pairing your medication with smart movement, solid nutrition, and regular monitoring—and by speaking up early if you notice new pain or mobility changes—you can greatly improve your chances of enjoying the upsides of GLP‑1 therapy while minimizing the downsides.


If you’re currently on a GLP‑1 drug, consider your next step:

  • Schedule a check‑in with your clinician to review bone and tendon risks in the context of your personal history.
  • Start or refine a gentle strength and mobility routine this week.
  • Track your protein, calcium, and vitamin D intake for a few days and adjust if needed.

You deserve care that supports your whole body—not just the number on the scale. With the evolving science as your guide and a thoughtful plan in place, that’s absolutely within reach.